Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

Brazil In Vitro Diagnostics Market - Growth, Trends, and Forecasts (2020 - 2025)

Published by Mordor Intelligence Pvt Ltd Product code 391030
Published Content info 80 Pages
Delivery time: 2-3 business days
Back to Top
Brazil In Vitro Diagnostics Market - Growth, Trends, and Forecasts (2020 - 2025)
Published: June 1, 2020 Content info: 80 Pages

Brazil is a country with a growing middle-class population, a stabilizing economy, increasing urban population, and a supportive government. The country is showing a major shift in the private healthcare sector, which is a supporting factor for the IVD market.

The Brazilian healthcare funding is supported by the Ministry of Health, which runs the government hospitals in the country. The rising interests of the Brazilian researchers in molecular testing technologies, prenatal screening, and point of care (POC) glucose testing are the primary factors augmenting the growth of the market studied.

According to the National Institute of Health, the prevalence of diabetes in Brazil was around 6.3% to 13.5% in 2016. This rising prevalence of diabetes in the country is propelling the growth of the in vitro diagnostics in Brazil. Therefore, factors, such as the rising interest of the Brazilian researchers in advanced diagnostics and high prevalence of chronic diseases, are contributing to the growth of the IVD market in the country.

Key Market Trends

Molecular Diagnostics Segment Spearheaded the Market Studied

  • Molecular diagnostic devices are used to analyze biological markers in the genome and proteome to detect pathogens or mutations. On the basis of technology used, molecular diagnostic devices can be segmented into chips and microarrays, mass spectroscopy, next-generation sequencing (NGS), polymerase chain reaction (PCR)-based methods, cytogenetic, and molecular imaging.
  • Factors, such as large outbreaks of bacterial and viral epidemics in the world, increasing demand for point-of-care diagnostics, and rapidly evolving technology, are driving the growth of the molecular diagnostics segment.
  • Molecular diagnostics and pharmacogenomics can be used to reduce the adverse effects and toxicity of pharmaceutical interventions and facilitate cost-effective therapy by avoiding unnecessary expensive drugs, optimizing doses and timing, and eliminating ineffective drugs. The field is rapidly evolving and remains attractive to academia and the industry.
  • The use of molecular diagnostic techniques in the development and subsequent administration of personalized medicine are likely to boost the market growth.

Competitive Landscape

Danaher Corporation, Roche Diagnostics, Becton, Dickinson and Company, bioMerieux, and Bio-Rad Laboratories Inc. are some of the major players in the market studied. The major companies are focusing on increasing technological advancements, in order to address customer needs, like fully automated systems, which reduces manual processes and consumables and also provides fast and accurate results.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support
Table of Contents
Product Code: 49227

Table of Contents


  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 High Prevalence of Chronic Diseases
    • 4.2.2 Increasing Use of Point-of-care (POC) Diagnostics
  • 4.3 Market Restraints
    • 4.3.1 Stringent Regulations
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry


  • 5.1 By Test Type
    • 5.1.1 Clinical Chemistry
    • 5.1.2 Molecular Diagnostics
    • 5.1.3 Immunodiagnostics
    • 5.1.4 Hematology
    • 5.1.5 Other Test Types
  • 5.2 By Product
    • 5.2.1 Instrument
    • 5.2.2 Reagent
    • 5.2.3 Other Products
  • 5.3 By Usability
    • 5.3.1 Disposable IVD Devices
    • 5.3.2 Reusable IVD Devices
  • 5.4 By Application
    • 5.4.1 Infectious Disease
    • 5.4.2 Diabetes
    • 5.4.3 Cancer/Oncology
    • 5.4.4 Cardiology
    • 5.4.5 Autoimmune Disease
    • 5.4.6 Nephrology
    • 5.4.7 Other Applications
  • 5.5 By End Users
    • 5.5.1 Diagnostic Laboratories
    • 5.5.2 Hospitals and Clinics
    • 5.5.3 Other End Users


  • 6.1 Company Profiles
    • 6.1.1 Abbott Laboratories
    • 6.1.2 Arkray Inc.
    • 6.1.3 Becton, Dickinson and Company
    • 6.1.4 bioMerieux
    • 6.1.5 Bio-Rad Laboratories Inc.
    • 6.1.6 Danaher Corporation
    • 6.1.7 QIAGEN
    • 6.1.8 Roche Diagnostics
    • 6.1.9 Siemens AG
    • 6.1.10 Thermo Fisher Scientific


Back to Top